Research programme: neurodegenerative disorders RNA interference-based therapeutics - Alnylam Pharmaceuticals

Drug Profile

Research programme: neurodegenerative disorders RNA interference-based therapeutics - Alnylam Pharmaceuticals

Latest Information Update: 15 May 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Sirna Therapeutics
  • Developer Alnylam Pharmaceuticals; Sirna Therapeutics
  • Class Nucleic acids
  • Mechanism of Action RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Neurodegenerative disorders
  • Discontinued Spinocerebellar degeneration

Most Recent Events

  • 09 May 2018 Preclinical trials in Neurodegenerative disorders in USA (Intrathecal)
  • 08 May 2018 Alnylam Pharmaceuticals plans to file an IND application for Central nervous system-targeted candidate in between late-2019 to early 2020
  • 06 Mar 2014 Alnylam Pharmaceuticals acquires Sirna Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top